Human immunodeficiency virus type 1 resistance or cross-resistance to nonnucleoside reverse transcriptase inhibitors currently under development as microbicides.
about
Resistance mutations outside the integrase coding region have an effect on human immunodeficiency virus replicative fitness but do not affect its susceptibility to integrase strand transfer inhibitorsPeptide and protein-based inhibitors of HIV-1 co-receptorsIn vitro resistance profile of the candidate HIV-1 microbicide drug dapivirineAntiviral drug resistance and the need for development of new HIV-1 reverse transcriptase inhibitors.The nonnucleoside reverse transcription inhibitor MIV-160 delivered from an intravaginal ring, but not from a carrageenan gel, protects against simian/human immunodeficiency virus-RT Infection.The griffithsin dimer is required for high-potency inhibition of HIV-1: evidence for manipulation of the structure of gp120 as part of the griffithsin dimer mechanism.The Need for Development of New HIV-1 Reverse Transcriptase and Integrase Inhibitors in the Aftermath of Antiviral Drug ResistanceCD4-mimetic sulfopeptide conjugates display sub-nanomolar anti-HIV-1 activity and protect macaques against a SHIV162P3 vaginal challenge.Using glycosaminoglycan/chemokine interactions for the long-term delivery of 5P12-RANTES in HIV prevention.Impaired human immunodeficiency virus type 1 replicative fitness in atypical viremic non-progressor individuals.HIV sexual transmission and microbicides.A novel vaginal microbicide containing the rationally designed anti-HIV compound HI-443 (N'-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridyl)] thiourea]).Protein/peptide-based entry/fusion inhibitors as anti-HIV therapies: challenges and future direction.Resistance and cross-resistance profile of the diaryltriazine NNRTI and candidate microbicide UAMC01398.In Vitro Cross-Resistance Profiles of Rilpivirine, Dapivirine, and MIV-150, Nonnucleoside Reverse Transcriptase Inhibitor Microbicides in Clinical Development for the Prevention of HIV-1 Infection.Increased replication capacity following evolution of PYxE insertion in Gag-p6 is associated with enhanced virulence in HIV-1 subtype C from East Africa.Novel method for simultaneous quantification of phenotypic resistance to maturation, protease, reverse transcriptase, and integrase HIV inhibitors based on 3'Gag(p2/p7/p1/p6)/PR/RT/INT-recombinant viruses: a useful tool in the multitarget era of antVaginal Mucosa and Drug Delivery
P2860
Q28533830-34B77F87-1B01-4D35-99AB-3FB26A5FED95Q30352117-F3A0E1F3-B041-4E1F-B0E8-00F8F79F1890Q35689311-66776C2A-48E0-485B-A495-8CA4CFC944BEQ36276790-2E64097C-12ED-4CE9-9B1A-2B0B0ECCB481Q36359133-55C06B9E-DFD7-4F0B-812F-4DDC4E57D5E2Q37036454-9D7DD212-39CB-419F-9CE5-C69C61076648Q37288671-1345874F-3817-4252-BCE8-C864555FA907Q37323948-9AE4A7F5-73C4-40DE-8037-A84196501630Q37458024-CF50FE1D-418C-4875-B54C-0B4F4B0BB91BQ37713470-FB3C3739-92C7-45F8-A429-4BED76066A30Q37853935-30FB14C8-8E08-4FF2-9105-E633128D0B99Q37980177-0C624FD2-C2AD-424B-917F-AEC2072AE785Q38574172-CCCCD4A1-993E-449B-A3EE-E1BC61E5DFF0Q38879629-C070D6CB-D842-4337-B30B-4AA6E8053549Q40200460-F1E0E2FF-5B39-4D4F-8579-DBA035CDE0C7Q40473808-380DFCDE-6BCB-4FE2-B127-2EB44F41E484Q42148219-4E5B6B75-3808-4626-A697-50CB8F4CB513Q57570821-D614BCDF-07B0-410E-BD27-2DF3CA4BB6C5
P2860
Human immunodeficiency virus type 1 resistance or cross-resistance to nonnucleoside reverse transcriptase inhibitors currently under development as microbicides.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Human immunodeficiency virus t ...... r development as microbicides.
@ast
Human immunodeficiency virus t ...... r development as microbicides.
@en
Human immunodeficiency virus t ...... r development as microbicides.
@nl
type
label
Human immunodeficiency virus t ...... r development as microbicides.
@ast
Human immunodeficiency virus t ...... r development as microbicides.
@en
Human immunodeficiency virus t ...... r development as microbicides.
@nl
prefLabel
Human immunodeficiency virus t ...... r development as microbicides.
@ast
Human immunodeficiency virus t ...... r development as microbicides.
@en
Human immunodeficiency virus t ...... r development as microbicides.
@nl
P2093
P2860
P356
P1476
Human immunodeficiency virus t ...... r development as microbicides.
@en
P2093
Ana C Vazquez
Guido Vanham
Johan Michiels
Katleen Vereecken
Katty Terrazas-Aranda
Kevin K Ariën
Leo Heyndrickx
Miguel E Quiñones-Mateu
Philippe Selhorst
P2860
P304
P356
10.1128/AAC.01426-10
P407
P577
2011-01-31T00:00:00Z